Aduro BioTech, J&J deal
Aduro granted Johnson & Johnson's Janssen Biotech Inc. subsidiary exclusive, worldwide rights to prostate cancer products based on Aduro's live-attenuated double-deleted Listeria monocytogenes (LADD) immunotherapy platform. The lead compound under the deal is Aduro's ADU-741, a Listeria-based immunotherapy targeting multiple undisclosed prostate-specific antigens that is in preclinical testing for prostate cancer. J&J declined to disclose plans for Phase I testing. The companies said the deal also includes a series of preclinical prostate-specific Listeria strains in the family of ADU-741.
Aduro is eligible to receive up to $365 million comprised of an upfront payment, license fees and milestones, plus tiered royalties. Janssen is responsible for all R&D, manufacturing and regulatory and commercial activities. The deal originated at J&J's California Innovation Center. ...